Immune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis
Open Access
- 2 April 2026
- journal article
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71777
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) are an important treatment option in bladder cancer, but clinical trials have demonstrated that they are associated with immune‐related adverse events (irAEs), such as rash, hypothyroidism, hyperthyroidism, and others. This study aimed to evaluate real‐world evidence of these irAEs using the FDA Adverse Event Reporting System (FAERS). Methods: We analyzed FAERS data through December 2024 to identify irAEs associated with atezolizumab, pembrolizumab, avelumab, and nivolumab in patients with bladder cancer. A case/non‐case pharmacovigilance analysis was conducted to assess the association between ICI monotherapy and specific irAEs, including rash, pruritus, hypothyroidism, hyperthyroidism, colitis, nephritis, myocarditis, pneumonitis, and myositis. Results: A total of 365 unique irAE reports were identified. Significant safety signals were observed for hyperthyroidism with atezolizumab (PRR: 3.51 [95% CI: 1.07–11.45]; ROR: 3.53 [95% CI: 1.07–11.61]; IC: 1.10 [95% CI: 0.33–1.87]), rash with pembrolizumab (PRR: 2.11 [95% CI: 1.17–3.80]; ROR: 2.14 [95% CI: 1.18–3.90]; IC: 0.44 [95% CI: 0.17–0.71]), and myositis with avelumab (PRR: 5.30 [95% CI: 1.35–20.82]; ROR: 5.47 [95% CI: 1.34–22.29]; IC: 1.95 [95% CI: 0.65–3.25]). While not reaching the threshold for statistical significance, nephritis with atezolizumab did not meet predefined signal detection criteria and should only be considered as hypothesis‐generating. A similar borderline pattern was observed for hypothyroidism with avelumab. Conclusion: The occurrence of irAEs varies by ICI agent among bladder cancer patients. These findings underscore the importance of post‐marketing surveillance in identifying real‐world safety signals. Proactive management and patient education are essential to mitigate irAEs and preserve quality of life.Keywords
This publication has 31 references indexed in Scilit:
- StatPearls2023
- Immune Checkpoint Inhibitor-Related Myositis: From Biology to BedsideInternational Journal of Molecular Sciences, 2020
- Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerJournal of Clinical Oncology, 2020
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2018
- Dermatologic Reactions to Immune Checkpoint InhibitorsAmerican Journal of Clinical Dermatology, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- CTLA-4 and PD-1 PathwaysAmerican Journal of Clinical Oncology, 2016
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance databaseBritish Journal of Clinical Pharmacology, 2011